Create a narrative

AstraZeneca Community

OM:AZN Community

1 Narratives written by author
6 Comments on narratives written by author
134 Fair Values set on narratives written by author

Create a narrative

UN

Community Contributor

Expect a future valuation of 22x as AstraZeneca bets on pipeline strength

Catalysts Most Immediate Catalyst (1–2 Years): Strong Oncology Portfolio Growth: AstraZeneca’s cancer drugs Tagrisso, Imfinzi, Enhertu, and Calquence continue gaining market share, driving double-digit revenue growth in oncology. Respiratory & Cardiovascular Expansion: New approvals and label expansions in Farxiga (diabetes/heart failure) and Tezspire (severe asthma) can drive meaningful sales upside.

SEK 2.56k

FV

46.9% undervalued

9.89%

Revenue growth p.a.

39

0

108

about 2 months ago